Followers | 20 |
Posts | 5538 |
Boards Moderated | 0 |
Alias Born | 01/04/2012 |
Tuesday, October 17, 2017 7:57:43 AM
The Fly
In my opinion, the offer will depend on whether Ani is accelerating the next step to get ready for a future co-promotion deal with AbbVie or if Abbvie is triggering the deal.
If we are looking at the next step you will see a company with a global sales force. Just like the BPAX - ANI deal, announcement regarding Libigel will not be made and we can expect to get shares in the acquiring company. Unlike the BPAX-ANI deal, where most shares were held by retail investors, ANI's shares are heavily owned by institutional investors more likely to vote with the BOD's recommendation. Sadly, had we known the full picture with the BAX-ANIP merger we may have taken the first offer. In the end BPAX shareholder's walked away with 43% of the merged company as opposed to 47%.
If on the other hand AbbVie is going for the whole enchilada and looking at a full buyout. It could be sizable. I believe Abbott labs influenced the clinical trial changes in November 2009 which led to the discoveries. If so they would be entitle to discount over another bidder coming off the street. Given that Abbvie paid $21 billion for Imbruvica a drug estimated to generate peak sales of $7 billion if all indications are approved. However Imbruvica was already on the market and on the way to reaching Blockbuster status. If the employee I spoke with was right all the indications for Libigel if approved is estimated to generate peak sales in excess $16 billion. Now this would have to be discounted for Abbvie's early collaboration and taking over the second part of the safety/efficacy study, in addition to the fact it is not approved yet. They are gaining ANI's manufacturing facilities,and pipeline.
Think about it, if as I suspect Abbvie was willing to pay $350 million for a Priority Review Voucher which in my opinion will be used for Libigel, a $12 billion, maybe more much for a buyout from AbbVie is not unreasonable.
I believe the reason for all the non-disclosure was BPAX wanted more than Abbott/AbbVie were willing to offer at the time. However AbbVie did not want the discoveries becoming public knowledge. Which could have made a buyout much more expensive when and if they decided to pull the trigger.
JMHO
Recent ANIP News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:03:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 08:50:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 01:13:56 PM
- ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 12:53:27 PM
- ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/16/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:23:15 PM
- ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution • GlobeNewswire Inc. • 09/13/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • GlobeNewswire Inc. • 09/11/2024 10:50:00 AM
- ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger • Business Wire • 09/11/2024 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 08:44:38 PM
- ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences • GlobeNewswire Inc. • 09/10/2024 06:09:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 12:29:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:21:44 PM
- ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes • GlobeNewswire Inc. • 08/13/2024 08:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:51:52 AM
- ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/08/2024 01:44:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:26:24 AM
- ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering • GlobeNewswire Inc. • 08/07/2024 11:00:55 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 10:57:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 10:53:07 AM
- ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance • GlobeNewswire Inc. • 08/06/2024 10:50:00 AM
- ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:30:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 09:27:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/18/2024 09:12:40 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM